Lymfocytutveckling och reglering
http://portal.research.lu.se/portal/en/persons/ewa-sitnicka-quinn(e833d81c-751c-4f6f-bee9-5e570e7ad9e4).html">Ewa Sitnicka Quinn is Research Group Leader for this research group
Filetype
http://portal.research.lu.se/portal/en/persons/ewa-sitnicka-quinn(e833d81c-751c-4f6f-bee9-5e570e7ad9e4).html">Ewa Sitnicka Quinn is Research Group Leader for this research group
Human immunodeficiency virus (HIV) is a major threat against health in many countries. Despite progress in treatments and more affordable drugs there is still a vast need for new findings which could further explain the mechanisms of HIV disease progression. Therefore, my research group explores the HIV genetic diversity, transmission dynamics and drug resistance. We combine a strong global health
Our research focuses on clinical and epidemiological aspects of gene-environment interaction in relation to human reproductive function. The clinical base of our research is closely linked to the Reproductive Medicine Centre at Skåne University Hospital, Malmö. This enables us to study both male and female reproduction, separately and in combination. Some important subareas of research include spe
In this group we study how metastatic processes depend on suppression of the immune response and how the immune system actually instead promotes breast cancer metastasis. The research has a strong translational character with clinical collaborations and primary material as base in all projects. The focus is on immunosuppressive cell populations and metastatic processes in breast cancer. Understand
Cancer imaging is a growing field with screening programs for secondary prevention through early detection and advances in therapeutics as key drivers. Since primary prevention strategies are lacking for many types of cancers, imaging has a pivotal role in early detection, diagnosis and treatment response evaluation. Our research group has a long-standing experience especially in mammography scree
Translational research on prostate cancer: Identification of molecular targets for development of new therapies in chemo- and hormone resistant prostate cancer. This includes: 1) In vitro studies and animal models. 2) Development and validation of biomarkers in tissue, blood and urine including circulating tumor cells. 3) Biobanking. 4) Clinical studies on imaging biomarkers for prognosis, predict